It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Psoriasis is an inflammatory skin disease with strong neutrophil (PMN) infiltration and high levels of the antimicrobial peptide, LL37. LL37 in complex with DNA and RNA is thought to initiate disease exacerbation via plasmacytoid dendritic cells. However, the source of nucleic acids supposed to start this initial inflammatory event remains unknown. We show here that primary murine and human PMNs mount a fulminant and self-propagating neutrophil extracellular trap (NET) and cytokine response, but independently of the canonical NET component, DNA. Unexpectedly, RNA, which is abundant in NETs and psoriatic but not healthy skin, in complex with LL37 triggered TLR8/TLR13-mediated cytokine and NET release by PMNs in vitro and in vivo. Transfer of NETs to naive human PMNs prompts additional NET release, promoting further inflammation. Our study thus uncovers a self-propagating vicious cycle contributing to chronic inflammation in psoriasis, and NET-associated RNA (naRNA) as a physiologically relevant NET component.
Antimicrobial peptide LL37 can bind nucleic acids and potentiate their sensing by endosomal TLRs. Here the authors show that LL37 binds to RNA from neutrophil extracellular traps (NETs), which amplifies inflammation and production of more LL37 and NETs via TLR8/13, suggesting that LL37 contribution to psoriasis may be fueled by NET-associated RNA.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Tübingen, Department of Immunology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
2 Johns Hopkins University School of Medicine, Department of Dermatology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
3 University of Tübingen, Department of Immunology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447) ; David Eisel, BioNTech, Mainz, Germany (GRID:grid.434484.b) (ISNI:0000 0004 4692 2203)
4 University Hospital Heidelberg, Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
5 NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany (GRID:grid.461765.7) (ISNI:0000 0000 9457 1306)
6 University of Tübingen, Department of Immunology, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447) ; University Hospital Tübingen, Department of General, Visceral and Transplant Surgery, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249) ; University Hospital Tübingen, Department of Clinical Pharmacology, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249)
7 Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
8 Research Group Innate Immunity, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), Deutsches Zentrum für Lungenforschung (DZL), Borstel, Germany (GRID:grid.418187.3) (ISNI:0000 0004 0493 9170)
9 University Children’s Hospital and Interdisciplinary Center for Infectious Diseases, University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447) ; Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
10 University Hospital Heidelberg, Department of Dermatology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
11 University Hospital Tübingen, Department of Dermatology, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249)
12 University Hospital Tübingen, Department of Dermatology, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249) ; Department of Dermatology, Charité – Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)